*
*
Scoring Key: 5=Strongly Agree 4= Somewhat agree 3=Neither agree nor disagree 2= Somewhat disagree 1=Strongly disagree NA=Not applicable
54321NA
The skills learned in this CME course enhanced my professional competence.
The skills learned in this CME course will be applied in the treatment of my patients.
*
5 = High level of confidence 4 = Moderately high level of confidence 3 = Average level of confidence 2 = Low level of confidence 1 = No level of confidence NA|Not applicable to my practice
54321
Implement updates on T cell-engaging therapies for myeloma?
Treat AL amyloidosis?
Assess myelodysplastic syndrome (MDS) and who to transplant and who not to transplant?
Treat intestinal microbiome in cancer immunotherapy?
*
Scoring Key: 5=Strongly satisfied 4= Somewhat satisfied 3=Neither satisfied nor dissatisfied 2= Somewhat dissatisfied 1=Strongly dissatisfied NA=Not Applicable
54321NA
Maintenance Therapy Post Autologous Transplants: Deos MRD status Affect the Treatmnet Choice?- Saad Usmani, M.D.
Redirecting Therapies for Relapse/Refractory Multiple Myeloma by CAR T and Bites- Adam Cohen, M.D.
Integration of CellMods into Treatment Approaches for Multiple Myeloma- Paul Richardson, M.D.
Insights on Adapting Treatments for Multiple Myeloma with New Immunotherapies In Countries with Limited or Intermediate Resources- Patricio Duarte, M.D.
How to Treat AL Amyloidosis in 2026? -Heather Landau, M.D.
Novel Therapies in Relapsed Diffuse Large B-Cell Lymphoma (DLBCL)- Matthew Matasar, M.D.
Novel Therapies in Chronic Lymphocytic Leukemia (CLL) and Fillicular Lymphoma (FL)- Craig Sauter, M.D.
Overcoming Treatment Resistance in T-All: Translation to the Clinic- Wendy Stock, M.D.
AML 2026: Is 7+3 Still The Standard of Care?- Richard Stone, M.D.
Updates on Targeted Therapies in Acute Myeloid Leukemia- Eytan Stein, M.D.
Novel Therapeutic Strategies in Myelofibrosis-Raajit Rampal, M.D.
The Role of Menin Inhibitors in Myelofibrosis- Firas El Chaer, M.D.
Myelofibrosis: Who to Transplant and Who Not to Transplant- Nicolaus Kroeger, M.D.
*
*
*
*
*
*
*
*